Perlmutter Roger M

See remarks, DirectorEikon Therapeutics, Inc. (EIKN) · full profile →Form 4 · filed Feb 10, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 6, 2026Conversion(C)285K285K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 6, 2026Conversion(C)856K0
Feb 6, 2026Conversion(C)1.3M0

Transaction Codes

C
Conversion of a derivative

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-044903) within minutes of acceptance. Every field above traces to the original document. Verify it directly: